TD Cowen Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $1200
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Tyler Van Buren maintains a Buy rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and raises the price target from $1030 to $1200.
July 23, 2024 | 5:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
TD Cowen analyst Tyler Van Buren maintains a Buy rating on Regeneron Pharmaceuticals and raises the price target from $1030 to $1200.
The raised price target and maintained Buy rating from a reputable analyst can positively influence investor sentiment and potentially drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100